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High-dose antipsychotic is defined as the total daily
dose of a single antipsychotic which exceeds the upper
limit stated in the summary of product characteristics or a
total daily dose of two or more antipsychotics which
exceeds the summary of product characteristics using the
widely known percentage method related to
chlorpromazine equivalents (1,2).
A significant number of patients with schizophrenia
and other chronic psychosis syndromes are prescribed
high dose antipsychotic treatments (HD-APT) despite the
fact that clinical guidelines recommend the routine use of
a single antipsychotic drug in a standard dose. 
In fact, prescriptions for high-dose and combined
antipsychotics are relatively common in clinical practice
(3,4). However, the results of published trials of HD-APT
for schizophrenia provide no evidence to support
effectiveness of using HD-APT, and in general such a
strategy is not recommended. 
Moreover, there is mounting evidence of higher
incidence rates of side effects and mortality associated
with HD-APT (5). Therefore, in keeping with the 2006
Council Report of the Royal College of Psychiatrists, we
are suggesting a mini-checklist which should be followed
prior to the initiation of and during the follow-up of HD-
APT if such treatment is clinically justified and required
in certain adult patients. 
This checklist is aimed at minimizing predicted or
unpredicted side-effects, particularly those related to the
cardiovascular system. 
1. All clinicians should re-evaluate the diagnosis and
assess compliance before starting HD-APT. Non-
efficacy due to poor compliance must be distinguished
from real non-efficacy. 
ÖZET:
Yüksek doz antipsikotik ilaç tedavisi; pratik cep
kontrol listesi 
Klinik k›lavuzlarda  flizofreni ve di¤er kronik psikotik psikoz
hastalar›nda rutin olarak standart doz tek bir antipsikotik
ilaç kullan›m›n›n  önerilmesine  ra¤men, ço¤u hastada  an-
tipsikotik ilaçlar›n   yüksek doz reçete  edildi¤ine iliflkin ka-
n›tlar vard›r. Klinik pratikte yüksek doz ve kombine antipsi-
kotik ilaç reçete edilmesi nispeten s›k görülür. Yay›nlanan
çal›flmalar›n sonuçlar›nda az kan›t olmas›ndan dolay› yük-
sek doz antipsikotik ilaç tedavisi   pek  tavsiye edilmez.  Ay-
r›ca,  yüksek doz antipsikotik tedavisinin  yan etkileri ve
mortalite   oran› da yüksektir.  Bu nedenle antipsikotik   te-
davi s›ras›nda öngörülen  ve öngörülmeyen  yan etkileri as-
gariye indirmeyi  amaçlayan pratik bir cep kontrol listesi su-
nuyoruz.
Anahtar sözcükler: Antipsikotik tedavi, kontrol listesi,
yüksek doz
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ABSTRACT:
High-dose antipsychotic medication; a practical
pocket checklist 
There is evidence that a significant number of patients
with schizophrenia and other chronic psychotic psychosis
are prescribed high-dose antipsychotic drugs despite the
fact that clinical guidelines recommend the routine use of
a single antipsychotic drug in a standard dose. The
prescriptions for high-dose and combined antipsychotic
drugs are relatively common in clinical practice. This occurs
despite the fact that results of published trials of high-dose
antipsychotic drug treatment for schizophrenia provide
little evidence to support effectiveness of using high-dose
antipsychotic treatment and most importantly such
strategy is not recommended. Moreover, there is
mounting evidence of higher incidence of side effects and
mortality associated with high dose antipsychotic
treatment. Therefore we are presenting a practical pocket
checklist which is aimed at minimizing predicted and
unpredicted side effects during such treatments. 
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2. Relevant education about HD-APT should be
provided to the patient, care givers, and next of kin,
and such education should involve a pharmacist, a
patient advocate and a wider clinical team. Informed
consent (ideally written) should be obtained from the
patient. 
3. The details of the HD-APT should be documented in
the case notes, including risk and benefit assessments,
aims and objectives and outcome assessments. Possible
contraindications (i.e. medical/neurological illness,
presence of medical/neurological high-risk factors,
syncope or fits) and possible drug-drug and food-drug
interactions with the HD-APT should be carefully
considered. If at all possible, pharmacogenetics
technology should be used to determine the activity of
relevant cytochrome P450 (CYP) enzymes and the
pharmaco-metabolic state of the patient.
4. Adequate service infrastructure and communication
should be provided between the prescriber and the
pharmacist, with regard to dispensing and
administration of the medication.
5. Prior to the initiation of HD-APT, an ECG should be
done to establish a baseline (in particular the QTc
interval) and exclude cardiac contraindications and a
long QT syndrome. An ECG should be repeated after
a few days and then every 1-3 months in the early
stages of HD-APT. Electrolytes, in particular K+, Ca2+
and others which may contribute to cardiac
arrhythmias, should be monitored. Liver enzymes
should be monitored if there is a medical and/or
pharmacokinetic concern. Renal function tests,
including urea and creatinine, should be done in
patients at risk for dehydration and such patients
should be counselled about and monitored for
rehydration. Although not standard practice, prolactin
levels may be useful as a very rough yet practical
indicator for dopamine-D2 receptor antagonism in the
brain and as a rough guide for the state of blood brain
barrier permeability. Full metabolic/endocrine
investigations should also be carried out as
appropriate. 
6. Dose escalation should be in relatively small
increments and allow adequate time for response. 
7. The use of other “as required” (p.r.n) psychotropic
medications should be minimized and monitored. 
8. The care and management structure of the patient
should be enhanced (i.e. including more frequent
assessments and visits). The effectiveness of HD-APT
should be regularly monitored and it should initially
be prescribed on a trial basis up to 3 months (a time-
limited trial) and continued only if clinically justified
by a significant improvement. 
9. The practice of HD-APT use should be regularly
reviewed and audited with colleagues.
